Compare MMYT & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMYT | EXAS |
|---|---|---|
| Founded | 2000 | 1995 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 11.0B |
| IPO Year | 2010 | N/A |
| Metric | MMYT | EXAS |
|---|---|---|
| Price | $73.51 | $101.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 20 |
| Target Price | ★ $120.00 | $76.38 |
| AVG Volume (30 Days) | 823.9K | ★ 10.3M |
| Earning Date | 01-22-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | $1,011,011,000.00 | ★ $3,082,033,000.00 |
| Revenue This Year | $19.90 | $19.40 |
| Revenue Next Year | $19.52 | $13.51 |
| P/E Ratio | $107.05 | ★ N/A |
| Revenue Growth | ★ 14.55 | 14.47 |
| 52 Week Low | $70.10 | $38.81 |
| 52 Week High | $123.00 | $101.87 |
| Indicator | MMYT | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 89.74 |
| Support Level | $70.75 | $100.98 |
| Resistance Level | $75.72 | $101.43 |
| Average True Range (ATR) | 2.58 | 2.25 |
| MACD | 0.69 | 0.53 |
| Stochastic Oscillator | 43.26 | 97.74 |
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.